TY - JOUR
T1 - The role of thrombocytapheresis in the management of extreme thrombocytosis
T2 - a 6 years’ experience from a tertiary care center
AU - Chenna, Deepika
AU - Polavarapu, Isha
AU - Kandasamy, Dhivya
AU - Mohan, Ganesh
AU - Shastry, Shamee
N1 - Publisher Copyright:
© 2021. Medicine And Pharmacy Reports. All Rights Reserved.
PY - 2021
Y1 - 2021
N2 - Background. According to the American Society for Apheresis (ASFA) guidelines, thrombocytapheresis is a Category II indication in symptomatic patients and is aCategory III indication when used as secondary or prophylactic treatment. The roleof thrombocytapheresis is to prevent untoward complications that might occur evenbefore the cytoreductive agents can exert their action.Methods. A retrospective analysis of patients who underwent thrombocytapheresisbetween 2012 to 2018 was conducted. Demographic details, complete blood counts,diagnosis and indication for thrombocytapheresis were noted.Results. A total of 12 patients with thrombocytosis were included in the study. Thecause of thrombocytosis was primary in 3 (25%) patients and secondary in 9 (75%)patients. The average percentage reduction in platelet count was 47.1% (range12.3%-65.64%). There was a significant decrease in platelet count, platelet crit, andmean platelet volume after the procedure when compared to pre-procedure.Conclusion. Thrombocytapheresis selectively reduces platelet counts with noeffect on other cellular and plasma components. The role of thrombocytapheresisin extreme thrombocytosis is to be considered for an immediate decrease in plateletcount and to minimize the risks associated with thrombocytosis
AB - Background. According to the American Society for Apheresis (ASFA) guidelines, thrombocytapheresis is a Category II indication in symptomatic patients and is aCategory III indication when used as secondary or prophylactic treatment. The roleof thrombocytapheresis is to prevent untoward complications that might occur evenbefore the cytoreductive agents can exert their action.Methods. A retrospective analysis of patients who underwent thrombocytapheresisbetween 2012 to 2018 was conducted. Demographic details, complete blood counts,diagnosis and indication for thrombocytapheresis were noted.Results. A total of 12 patients with thrombocytosis were included in the study. Thecause of thrombocytosis was primary in 3 (25%) patients and secondary in 9 (75%)patients. The average percentage reduction in platelet count was 47.1% (range12.3%-65.64%). There was a significant decrease in platelet count, platelet crit, andmean platelet volume after the procedure when compared to pre-procedure.Conclusion. Thrombocytapheresis selectively reduces platelet counts with noeffect on other cellular and plasma components. The role of thrombocytapheresisin extreme thrombocytosis is to be considered for an immediate decrease in plateletcount and to minimize the risks associated with thrombocytosis
UR - http://www.scopus.com/inward/record.url?scp=85124486241&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124486241&partnerID=8YFLogxK
U2 - 10.15386/mpr-1954
DO - 10.15386/mpr-1954
M3 - Article
AN - SCOPUS:85124486241
SN - 2602-0807
VL - 94
SP - 434
EP - 439
JO - Medicine and Pharmacy Reports
JF - Medicine and Pharmacy Reports
IS - 4
ER -